Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector - a Unicenter Phase I/II Clinical Trial
Sponsor: University Hospital Heidelberg
A PHASE1/PHASE2 clinical study on Acute Lymphoblastic Leukemia, Adult and Acute Lymphoblastic Leukemia, Pediatric, this trial is actively recruiting participants. The trial is conducted by University Hospital Heidelberg and has accumulated 8 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2019 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2018 — Nov 2019 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Sep 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital Heidelberg
For direct contact, visit the study record on ClinicalTrials.gov .